A large number of traditional pharmaceutical companies are testing innovation and making efforts on ADCs and CAR-T

【Pharmaceutical Network Industry News】Recently, Northeast Pharmaceutical disclosed that its subsidiary established in order to accelerate the implementation of the ADC drug and CAR-T cell therapy technical cooperation project of the United States MedAbome Company has completed industrial and commercial registration
.
It is understood that on September 20 this year, the board of directors of Northeast Pharmaceutical deliberated and passed the "Proposal on the Company's Proposed Establishment of Subsidiaries for Foreign Investment", and agreed that the company should invest 500 million yuan of its own funds to establish a wholly-owned subsidiary, thereby accelerating the implementation of ADC drugs and CAR-T cell therapy technical cooperation projects introduced by agreement with the United States MedAbome
.
At the beginning, the subsidiary focused on promoting the research and development of cooperation projects, meeting the preparation of clinical products, and building a small production platform
for culture media.
In addition, in early September, Northeast Pharmaceutical also signed the "MAb11-22.
1 antibody project transfer, cooperative development and technical service agreement"
with the United States MedAbome.
According to public information, MAb11-22.
1 is a monoclonal antibody
developed by MedAbome that can selectively recognize malignant tumor cells without reacting with normal peripheral blood cells and major organ tissues.
Industry analysts believe that the above actions of Northeast Pharmaceutical fully reflect that it is promoting the progress of research and development at full speed through various ways and steadily increasing the proportion of
new product revenue.
In fact, with the help of the "dividend" of mixed reform, Northeast Pharmaceutical is vigorously promoting mechanism innovation, management innovation and technological innovation in recent years, among which it has continuously accelerated
in research and development.
In 2019, according to the new development goals, the company focused on superior product series and disease treatment fields, and fully promoted the implementation of
more than 100 key R&D projects.
In 2020, the company has carried out 113 R&D projects
.
It is worth mentioning that in the next 5 years, in addition to increasing investment in self-research, Northeast Pharmaceutical also plans to introduce 2-3 clinical stage chemical innovative drugs and 1-2 clinical stage biological innovative drugs, and obtain 3-7 generic drug production approvals every year, steadily increasing the proportion
of new product revenue.
It can be seen from the above that in the face of the environment of huge development potential and increasing competition in the pharmaceutical market, innovation has obviously become the driving force for the development of
pharmaceutical companies.
In the field of ADC drugs and CAR-T cell therapy, with huge market prospects, it is also becoming the main direction
of more and more pharmaceutical companies.
In recent years, in fact, many traditional pharmaceutical companies are laying out the field of
bioinnovative drugs through self-research and introduction/cooperation, or by establishing independent subsidiaries and acquiring new companies.
At present, the traditional pharmaceutical companies involved in ADC include Shanghai Pharmaceutical, Sihuan Pharmaceutical, CSPC Pharmaceutical Group, Qilu Pharmaceutical, Zhenbaodao Pharmaceutical, Kelun Pharmaceutical, etc
.
Among them, Zhenbao Island has successively invested in a number of ADC R&D enterprises such as Teris, Duoxi Biologics, and Akeris, and also invested 1.
7 billion yuan to build the Hangzhou biopharmaceutical project focusing on the research and development of anti-tumor ADC drugs, and the layout of ADC drugs has gradually been systematized
.
In the field of CAR-T, there are relatively few traditional pharmaceutical companies and most of the pipelines are in the preclinical stage, such as Shanghai Pharmaceutical, Boan Biotechnology, a holding subsidiary of Luye Pharmaceutical
.
Among them, on February 25, Luye Pharmaceutical issued an announcement that the new indication marketing application of its subsidiary Boan Biologics antitumor drug bevacizumab injection has been approved by the State Food and Drug Administration for the treatment
of epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, as well as cervical cancer 。 However, it should be noted that bioinnovative drugs such as ADC and CAR-T require large capital investment, long R&D cycle and high risk, higher requirements for technical talents and platforms, and great requirements for technology and product originality and differentiated competition.
In addition, whether the product can be successfully commercialized in the future is also susceptible to some uncertainties
.
Therefore, the industry suggests that companies that want to test the waters of innovation need to be more cautious.

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.